Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: A systematic review and meta-analysis.

Autor: Milrod CJ; Department of Hematology/Oncology, Brown University, Providence, Rhode Island, USA., Kim KW; Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, USA., Raker C; Lifespan Biostatistics, Epidemiology, Research Design, and Informatics, Rhode Island Hospital, Providence, Rhode Island, USA., Ollila TA; Department of Hematology/Oncology, Brown University, Providence, Rhode Island, USA., Olszewski AJ; Department of Hematology/Oncology, Brown University, Providence, Rhode Island, USA., Pelcovits A; Department of Hematology/Oncology, Brown University, Providence, Rhode Island, USA.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2024 Jun; Vol. 204 (6), pp. 2237-2241. Date of Electronic Publication: 2024 Apr 04.
DOI: 10.1111/bjh.19449
Abstrakt: Although progression-free survival (PFS) is a commonly used surrogate end-point for clinical trials of follicular lymphoma (FL), no analyses have evaluated the strength of surrogacy for PFS with overall survival (OS). A systematic review was performed and 20 studies (total participants, 10 724) met final inclusion criteria. PFS was weakly associated with OS (correlation coefficient; 0.383, p < 0.001). The coefficient of determination was 0.15 (95% CI: 0.002-0.35) suggesting 15% of OS variance could be explained by changes in PFS. This challenges the role for PFS as a surrogate end-point for clinical trials and drug approvals.
(© 2024 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: